Evidence map›Paper›PMID 40269773›Full record

ArticleBMC cancer2025

Abnormal phosphorylation of human LRH1 at Ser510 predicts poor prognosis and promotes cell viability in lung squamous cell carcinoma.

Hayato Mine, Kotaro Sugimoto, Makoto Kobayashi, Hironori Takagi, Naoyuki Okabe, Satoshi Muto, Yasuyuki Kobayashi, Yuko Hashimoto, Hiroyuki Suzuki, Hideki Chiba

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hayato Mine *Department of Basic Pathology, Fukushima Medical University School of Medicine, Fukushima, 960- 1295, Japan.
Kotaro Sugimoto *Department of Basic Pathology, Fukushima Medical University School of Medicine, Fukushima, 960- 1295, Japan. sugikota@fmu.ac.jp.
Makoto KobayashiDepartment of Basic Pathology, Fukushima Medical University School of Medicine, Fukushima, 960- 1295, Japan.
Hironori TakagiDepartment of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, 960- 1295, Japan.
Naoyuki OkabeDepartment of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, 960- 1295, Japan.
Satoshi MutoDepartment of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, 960- 1295, Japan.
Yasuyuki KobayashiDepartment of Diagnostic Pathology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.
Yuko HashimotoDepartment of Diagnostic Pathology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.
Hiroyuki SuzukiDepartment of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, 960- 1295, Japan.
Hideki ChibaDepartment of Basic Pathology, Fukushima Medical University School of Medicine, Fukushima, 960- 1295, Japan. hidchiba@fmu.ac.jp.

Funding

Japan Society for the Promotion of Science 22K08896Japan Society for the Promotion of Science 23H02703
6 · The paper itself

Abstract

The nuclear receptor liver receptor homolog 1 (LRH1)/NR5A2 is aberrantly expressed in diverse cancer types, including liver and lung cancers. Since we previously showed that excessive phosphorylation of human LRH1 at S510 (hLRH1

Indexed as

Carcinoma, Squamous CellLung NeoplasmsReceptors, Cytoplasmic and NuclearAdultAgedBiomarkers, TumorCell Line, TumorCell SurvivalFemaleHumansKaplan-Meier EstimateMaleMiddle AgedPhosphorylationPrognosisSerineBiomarkers, TumorNR5A2 protein, humanReceptors, Cytoplasmic and NuclearSerineBiomarkerLiver receptor homolog 1Lung adenocarcinomaLung cancerNR5A2Nuclear receptorTherapeutic target

Identifiers

PMID40269773
PMCPMC12016208

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.